Department of Biochemistry, University of Pavia, via Taramelli 3b, 27100 Pavia, Italy.
J Biol Chem. 2011 Jan 21;286(3):2121-31. doi: 10.1074/jbc.M110.178376. Epub 2010 Nov 10.
The discovery of methods suitable for the conversion in vitro of native proteins into amyloid fibrils has shed light on the molecular basis of amyloidosis and has provided fundamental tools for drug discovery. We have studied the capacity of a small library of tetracycline analogues to modulate the formation or destructuration of β2-microglobulin fibrils. The inhibition of fibrillogenesis of the wild type protein was first established in the presence of 20% trifluoroethanol and confirmed under a more physiologic environment including heparin and collagen. The latter conditions were also used to study the highly amyloidogenic variant, P32G. The NMR analysis showed that doxycycline inhibits β2-microglobulin self-association and stabilizes the native-like species through fast exchange interactions involving specific regions of the protein. Cell viability assays demonstrated that the drug abolishes the natural cytotoxic activity of soluble β2-microglobulin, further strengthening a possible in vivo therapeutic exploitation of this drug. Doxycycline can disassemble preformed fibrils, but the IC(50) is 5-fold higher than that necessary for the inhibition of fibrillogenesis. Fibril destructuration is a dynamic and time-dependent process characterized by the early formation of cytotoxic protein aggregates that, in a few hours, convert into non-toxic insoluble material. The efficacy of doxycycline as a drug against dialysis-related amyloidosis would benefit from the ability of the drug to accumulate just in the skeletal system where amyloid is formed. In these tissues, the doxycycline concentration reaches values several folds higher than those resulting in inhibition of amyloidogenesis and amyloid destructuration in vitro.
适用于将天然蛋白质体外转化为淀粉样纤维的方法的发现,揭示了淀粉样变性的分子基础,并为药物发现提供了基本工具。我们研究了一小部分四环素类似物的能力,以调节β2-微球蛋白纤维的形成或去结构。在 20%三氟乙醇存在下首次建立了野生型蛋白纤维生成的抑制作用,并在包括肝素和胶原蛋白在内的更生理环境中得到了证实。后一种条件也用于研究高度淀粉样变变体 P32G。NMR 分析表明,强力霉素通过涉及蛋白质特定区域的快速交换相互作用抑制β2-微球蛋白自组装并稳定类似天然的物质。细胞活力测定表明,该药物可消除可溶性β2-微球蛋白的天然细胞毒性活性,进一步增强了该药物在体内治疗中的潜在应用。强力霉素可以分解原纤维,但 IC(50)比抑制纤维生成所需的浓度高 5 倍。纤维去结构是一个动态和时间依赖性过程,其特征是早期形成细胞毒性蛋白质聚集体,在数小时内转化为无毒的不溶性物质。强力霉素作为一种针对透析相关性淀粉样变性的药物的疗效将受益于药物仅在形成淀粉样蛋白的骨骼系统中积累的能力。在这些组织中,强力霉素的浓度达到了几个数量级,高于体外抑制淀粉样生成和淀粉样去结构所需的浓度。